{
"id":"mk19_b_rm_s2",
"subspecialtyId":"rm",
"title":"Principles of Therapeutics",
"jsonContent":{
"type":"section",
"id":"mk19_b_rm_s2",
"title":{
"__html":"Principles of Therapeutics"
},
"titleNode":{
"type":"section-title",
"hlId":"edc666",
"children":[
"Principles of Therapeutics"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s2_1",
"title":{
"__html":"Overview"
},
"titleNode":{
"type":"section-title",
"hlId":"3b8782",
"children":[
"Overview"
]
},
"children":[
{
"type":"p",
"hlId":"51c58c",
"children":[
"This section reviews the indications for use, mechanisms of action, major toxicities, and monitoring requirements of medications used in rheumatologic disease. Drug applications in specific disease states are elaborated on in their respective sections."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_2",
"title":{
"__html":"Anti-Inflammatory Agents"
},
"titleNode":{
"type":"section-title",
"hlId":"9d19ff",
"children":[
"Anti-Inflammatory Agents"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s2_2_1",
"title":{
"__html":"Glucocorticoids"
},
"titleNode":{
"type":"section-title",
"hlId":"adb71f",
"children":[
"Glucocorticoids"
]
},
"children":[
{
"type":"p",
"hlId":"f84a53",
"children":[
"Glucocorticoids are effective in many rheumatologic diseases, including rheumatoid arthritis (RA), acute crystal arthropathy, systemic vasculitis, polymyalgia rheumatica, systemic lupus erythematosus, inflammatory myopathies, and autoinflammatory diseases. Advantages include rapid onset, ease of use, low cost, and universal availability; they are often disease modifying and sometimes lifesaving."
]
},
{
"type":"p",
"hlId":"e0d22c",
"children":[
"Adverse effects include osteoporosis, immunosuppression, skin fragility, glaucoma, cataracts, weight gain, diabetes mellitus, hypertension, psychomotor agitation, osteonecrosis, and suppression of the hypothalamic-pituitary-adrenal axis. These effects are more likely with higher doses and longer treatment."
]
},
{
"type":"p",
"hlId":"b6162c",
"children":[
"The immunosuppressive adverse effects of glucocorticoids are apparent at moderate (prednisone at ≥20 mg/d) and high doses but can also occur at lower doses (e.g., 7.5 mg/d for more than a few weeks). The American College of Rheumatology (ACR) recommends that patients who are anticipated to be receiving long-term glucocorticoid treatment (prednisone at ≥2.5 mg/d for ≥3 months) should have a baseline clinical risk assessment for osteoporosis within 3 to 6 months of initiation of therapy. Those with risk factors and those older than age 40 years should also undergo periodic bone mineral density testing. Furthermore, those at moderate or high risk for osteoporotic fractures who are prescribed long-term glucocorticoid therapy should be treated prophylactically with an antiresorptive agent, preferably an oral bisphosphonate."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_2_2",
"title":{
"__html":"NSAIDs"
},
"titleNode":{
"type":"section-title",
"hlId":"d3bf03",
"children":[
"NSAIDs"
]
},
"children":[
{
"type":"p",
"hlId":"e56559",
"children":[
"NSAIDs prevent prostaglandin production by inhibiting the two isoforms of cyclooxygenase (COX): COX-1 and COX-2. COX-2 is an inducible enzyme typically expressed in inflammatory milieus, whereas COX-1 is constitutively expressed and helps maintain organismal homeostasis. Nearly all available COX inhibitors are nonselective (i.e., they inhibit both COX isoforms), down-regulating prostaglandin production in inflammatory states, and interfering with functions of prostanoids (e.g., renal blood flow and gut mucosal integrity maintenance) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t08",
"wrapId":"1",
"children":[
"Table 8"
]
}
]
},
")"
]
},
". Nonselective COX inhibitors also inhibit thromboxane A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
", thereby inhibiting platelet function."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_rm_t08"
]
},
{
"type":"p",
"hlId":"2fe9ff",
"children":[
"Although they alleviate symptoms, COX inhibitors are not disease modifying, with the possible exception of ankylosing spondylitis. Major concerns surrounding all COX inhibitors include increased risk for gastrointestinal bleeding and adverse cardiovascular events; therefore, they should be prescribed at the lowest dose for the shortest time possible. COX inhibitors should generally be avoided in patients receiving concomitant anticoagulation."
]
},
{
"type":"p",
"hlId":"59150f",
"children":[
"NSAIDs vary with regard to kinetics, COX-1/2 selectivity, and other features, and they carry somewhat different degrees of cardiovascular and other risks; having experience with several different NSAIDs is beneficial in clinical practice."
]
},
{
"type":"p",
"hlId":"9faa94",
"children":[
"A topical preparation of the NSAID diclofenac is available both by prescription and over the counter for arthritis. It poses a lower risk for systemic adverse effects compared with oral NSAIDs. Topical NSAIDs are strongly recommended for patients with knee osteoarthritis and conditionally recommended for patients with hand osteoarthritis. Topical diclofenac may also be preferred for patients at high risk for toxicity from oral NSAIDs or those 75 years of age or older."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_2_3",
"title":{
"__html":"Colchicine"
},
"titleNode":{
"type":"section-title",
"hlId":"56ec19",
"children":[
"Colchicine"
]
},
"children":[
{
"type":"p",
"hlId":"79e665",
"children":[
"Colchicine inhibits microtubules, impairs neutrophil function, and inhibits inflammasome-mediated interleukin-1 activation. Inflammasome is a central signaling system that regulates the inflammatory response. It is most commonly used for gout and acute calcium pyrophosphate crystal arthritis (pseudogout). It is also a treatment for hypersensitivity vasculitis and familial Mediterranean fever."
]
},
{
"type":"p",
"hlId":"e1db4f",
"children":[
"Gastrointestinal adverse effects (particularly diarrhea) are common but reversible with dose adjustment or discontinuation. With overdose, severe (even fatal) myelosuppression can occur. Dosing must be adjusted for kidney disease. When given over the long term, colchicine can rarely cause neuromuscular toxicity, particularly if coadministered with strong CYP3A4 inhibitors (e.g., clarithromycin) that reduce the hepatic catabolism of colchicine. Such coadministration should be avoided."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"883c92",
"children":[
"Patients anticipated to be receiving long-term glucocorticoid treatment (prednisone at ≥2.5 mg/d for ≥3 months) should have a baseline clinical risk assessment for osteoporosis within 3 to 6 months of initiation of therapy."
]
},
{
"type":"keypoint",
"hlId":"cff7aa",
"children":[
"Because of the increased risk for gastrointestinal bleeding and adverse cardiovascular and renal events, cyclooxygenase inhibitors should be prescribed at the lowest dose for the shortest time possible."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_3",
"title":{
"__html":"Analgesics and Pain Pathway Modulators"
},
"titleNode":{
"type":"section-title",
"hlId":"3d3c34",
"children":[
"Analgesics and Pain Pathway Modulators"
]
},
"children":[
{
"type":"p",
"hlId":"9b83ed",
"children":[
"Pain is a central symptom for patients with inflammatory arthritis and osteoarthritis. It is important to use a patient-centered approach while managing pain in these patients. In addition to pharmacologic interventions, treatment should include patient education, guidance on physical activity and exercise, orthotics, psychological and social interventions, sleep hygiene education, and, if indicated, sleep interventions."
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_3_1",
"title":{
"__html":"Acetaminophen"
},
"titleNode":{
"type":"section-title",
"hlId":"07d079",
"children":[
"Acetaminophen"
]
},
"children":[
{
"type":"p",
"hlId":"f925ed",
"children":[
"The efficacy of acetaminophen for osteoarthritis and lower back pain has been questioned. Controlled trials and meta-analyses have shown no benefit from the drug, even at high doses. However, because of its favorable safety profile, it may be empirically tried for short-term or add-on therapy. The daily dosage should not exceed 3000 mg/d. ACR guidelines conditionally recommend acetaminophen for patients with knee, hip, or hand osteoarthritis and limited pharmacologic options."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_3_2",
"title":{
"__html":"Tramadol"
},
"titleNode":{
"type":"section-title",
"hlId":"85e01b",
"children":[
"Tramadol"
]
},
"children":[
{
"type":"p",
"hlId":"b7f1d8",
"children":[
"Tramadol is a mixed opioid analgesic and weak serotonin-norepinephrine reuptake inhibitor (SNRI) with a lower potential for addiction than traditional opioids. It may be considered in a limited number of patients for whom other methods of analgesia were ineffective or not tolerated. Adverse effects may include nausea, vomiting, constipation, lightheadedness, and sedation. Traditional opioids should generally be avoided in rheumatologic treatment because of limited efficacy, high toxicity, and high potential for dependence. See ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s5_3_2_2",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
" for discussion of risk assessment and monitoring of long-term opioid therapy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_3_3",
"title":{
"__html":"Serotonin-Norepinephrine Reuptake Inhibitors"
},
"titleNode":{
"type":"section-title",
"hlId":"b9a55c",
"children":[
"Serotonin-Norepinephrine Reuptake Inhibitors"
]
},
"children":[
{
"type":"p",
"hlId":"17d433",
"children":[
"Duloxetine is an SNRI approved by the FDA for the management of chronic musculoskeletal pain and fibromyalgia. Duloxetine provides modest pain relief for knee osteoarthritis, chronic lower back pain, and fibromyalgia. Milnacipran is another SNRI approved for fibromyalgia. To avoid withdrawal symptoms, patients must be slowly weaned off SNRIs when the drug is discontinued."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_3_4",
"title":{
"__html":"Gabapentinoids"
},
"titleNode":{
"type":"section-title",
"hlId":"7e4fd4",
"children":[
"Gabapentinoids"
]
},
"children":[
{
"type":"p",
"hlId":"65eedc",
"children":[
"Gabapentinoids (gabapentin and pregabalin) inhibit voltage-gated calcium channels, thereby reducing pain signaling from the periphery to the central nervous system. Pregabalin is FDA approved for fibromyalgia. Common adverse effects (dizziness, disequilibrium, somnolence, weight gain, peripheral edema, and cognitive difficulties) may limit its utility. The FDA has issued a safety alert stating that serious breathing difficulties may occur in patients using gabapentin or pregabalin who have respiratory risk factors (e.g., older persons, patients with COPD, and patients receiving opioids and other drugs that depress the central nervous system)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"00f148",
"children":[
"The American College of Rheumatology conditionally recommends acetaminophen for knee, hip, and hand osteoarthritis."
]
},
{
"type":"keypoint",
"hlId":"967430",
"children":[
"Traditional opioids should generally be avoided in rheumatologic treatment because of limited efficacy, high toxicity, and high potential for dependence."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4",
"title":{
"__html":"Disease-Modifying Antirheumatic Drugs"
},
"titleNode":{
"type":"section-title",
"hlId":"95cd89",
"children":[
"Disease-Modifying Antirheumatic Drugs"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s2_4_1",
"title":{
"__html":"Nonbiologic Disease-Modifying Antirheumatic Drugs"
},
"titleNode":{
"type":"section-title",
"hlId":"cc2b08",
"children":[
"Nonbiologic Disease-Modifying Antirheumatic Drugs"
]
},
"children":[
{
"type":"p",
"hlId":"9db401",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t09",
"wrapId":"2",
"children":[
"Table 9"
]
}
]
},
" summarizes the mechanisms of action, indications, and common monitoring parameters of various nonbiologic disease-modifying antirheumatic drugs (DMARDs). See ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s2_6",
"children":[
"Medications and Pregnancy"
]
},
" for information on these drugs in pregnancy."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_rm_t09"
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_1",
"title":{
"__html":"Methotrexate"
},
"titleNode":{
"type":"section-title",
"hlId":"b98cff",
"children":[
"Methotrexate"
]
},
"children":[
{
"type":"p",
"hlId":"96decf",
"children":[
"Methotrexate is a first-line medication for RA and other autoimmune diseases. Once-weekly dosing is generally 10 to 25 mg; the drug can be given orally or subcutaneously. At doses above 15 mg, parenteral administration is more reliable but much more expensive."
]
},
{
"type":"p",
"hlId":"977c56",
"children":[
"Potential adverse effects include headaches, fatigue, and nausea (particularly around the time of weekly dosing). Hepatotoxicity and cytopenia can occur (especially macrocytic anemia), and dose adjustment is required with kidney disease. Methotrexate should be avoided in patients with significant hepatic or kidney disease and is absolutely contraindicated around pregnancy. Folic acid supplements minimize toxicity while preserving efficacy. Limiting alcohol intake is recommended."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_2",
"title":{
"__html":"Hydroxychloroquine"
},
"titleNode":{
"type":"section-title",
"hlId":"476428",
"children":[
"Hydroxychloroquine"
]
},
"children":[
{
"type":"p",
"hlId":"5b745c",
"children":[
"Hydroxychloroquine is an immunomodulator widely used in systemic lupus erythematosus, in which it decreases mortality and the likelihood of nephritis. It is rarely sufficient as single-drug therapy for RA but is useful as an adjunctive therapy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_3",
"title":{
"__html":"Sulfasalazine"
},
"titleNode":{
"type":"section-title",
"hlId":"121888",
"children":[
"Sulfasalazine"
]
},
"children":[
{
"type":"p",
"hlId":"85f634",
"children":[
"Sulfasalazine is used to treat RA and nonaxial psoriatic arthritis. It is now most frequently used as part of combination DMARD therapy for RA. Serious adverse effects include blood dyscrasias, hepatitis, and hypersensitivity reactions. Because of the benefit of its salicylate moiety for inflammatory bowel disease, it may be a useful strategy for patients with inflammatory bowel disease–associated arthritis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_4",
"title":{
"__html":"Leflunomide"
},
"titleNode":{
"type":"section-title",
"hlId":"14a480",
"children":[
"Leflunomide"
]
},
"children":[
{
"type":"p",
"hlId":"b27e44",
"children":[
"Leflunomide is FDA approved for RA and psoriatic arthritis, with efficacy similar to that of methotrexate. Patients must be monitored for hepatotoxicity and myelosuppression. Other common adverse effects include nausea, headaches, rash, diarrhea, and elevation of serum aminotransferase levels. Peripheral neuropathy is an uncommon adverse effect that is usually self-limited if the drug is discontinued. Leflunomide is highly teratogenic and absolutely contraindicated around pregnancy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_5",
"title":{
"__html":"Azathioprine"
},
"titleNode":{
"type":"section-title",
"hlId":"ac0373",
"children":[
"Azathioprine"
]
},
"children":[
{
"type":"p",
"hlId":"6b657a",
"children":[
"Azathioprine is an immunosuppressant used in various inflammatory diseases. Its primary toxicity is myelosuppression, especially in individuals with a decreased or absent thiopurine methyltransferase enzyme. Because azathioprine is metabolized by xanthine oxidase, concomitant use with xanthine oxidase inhibitors (allopurinol, febuxostat) is contraindicated."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_6",
"title":{
"__html":"Cyclophosphamide"
},
"titleNode":{
"type":"section-title",
"hlId":"3ce44b",
"children":[
"Cyclophosphamide"
]
},
"children":[
{
"type":"p",
"hlId":"589e1d",
"children":[
"Cyclophosphamide has a rapid onset of action (days to weeks). It is used to treat vasculitis, life-threatening complications of systemic lupus erythematosus, and interstitial lung disease. Cyclophosphamide has largely been displaced by safer drugs for first-line treatment of ANCA-associated vasculitis and lupus nephritis (rituximab and mycophenolate mofetil, respectively) but is still used in severe cases or when these agents fail. Serious potential adverse effects include severe immunosuppression, leukopenia, hemorrhagic cystitis, and ovarian failure, as well as long-term risk for bladder cancer, leukemia, and lymphoma."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_7",
"title":{
"__html":"Mycophenolate Mofetil"
},
"titleNode":{
"type":"section-title",
"hlId":"fd4d9d",
"children":[
"Mycophenolate Mofetil"
]
},
"children":[
{
"type":"p",
"hlId":"5c26f8",
"children":[
"Mycophenolate mofetil is the first-line agent for lupus nephritis and may be effective for systemic sclerosis with associated interstitial lung disease. Gastrointestinal adverse effects, including diarrhea, are common. Myelosuppression may occur."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_8",
"title":{
"__html":"Calcineurin Inhibitors"
},
"titleNode":{
"type":"section-title",
"hlId":"9e1b04",
"children":[
"Calcineurin Inhibitors"
]
},
"children":[
{
"type":"p",
"hlId":"df71e4",
"children":[
"Calcineurin inhibitors include cyclosporine, tacrolimus, and voclosporin. Cyclosporine is now rarely used for rheumatologic conditions because of renal adverse effects, hypertension, hyperuricemia (often presenting as gout), and need for frequent drug level monitoring. Tacrolimus may be considered as alternative therapy for some patients with lupus nephritis. Voclosporin, a next-generation calcineurin inhibitor with higher potency and improved side-effect profile, is FDA approved for lupus nephritis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_9",
"title":{
"__html":"Janus Kinase Inhibitors"
},
"titleNode":{
"type":"section-title",
"hlId":"a60108",
"children":[
"Janus Kinase Inhibitors"
]
},
"children":[
{
"type":"p",
"hlId":"1dd6d4",
"children":[
"Tofacitinib is an oral agent that inhibits Janus kinase (JAK) 1/3 signaling. Tofacitinib is FDA approved for RA and psoriatic arthritis, with efficacy equal to that of biologic DMARDs. Newer JAK inhibitors approved for rheumatic diseases include baricitinib (JAK1/2) and upadacitinib (JAK1)."
]
},
{
"type":"p",
"hlId":"b4a7da",
"children":[
"The FDA warns that tofacitinib and possibly the newer JAK inhibitors (baricitinib and upadacitinib) are associated with an increased risk for myocardial infarction or stroke, cancer, blood clots, and death. Other risks include hyperlipidemia, hepatotoxicity, leukopenia, and reactivation of zoster (at a rate higher than seen with biologic therapies)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_1_10",
"title":{
"__html":"Apremilast"
},
"titleNode":{
"type":"section-title",
"hlId":"a1b7af",
"children":[
"Apremilast"
]
},
"children":[
{
"type":"p",
"hlId":"b51f90",
"children":[
"Apremilast is modestly effective for psoriasis and psoriatic arthritis. It does not cause immunosuppression or myelosuppression. However, apremilast is less efficacious than biologic DMARDs and has a slow onset of action, and its effect on progression of erosive damage is unknown. Risks include gastrointestinal adverse effects (mainly nausea and diarrhea) and weight loss. It should be used with caution in patients with a history of depression. Apremilast is also FDA approved for treatment of oral ulcers in Behçet syndrome."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"967a3a",
"children":[
"Methotrexate is a first-line medication for rheumatoid arthritis and other autoimmune diseases."
]
},
{
"type":"keypoint",
"hlId":"624362",
"children":[
"Hydroxychloroquine decreases mortality and the likelihood of developing nephritis in patients with systemic lupus erythematosus."
]
},
{
"type":"keypoint",
"hlId":"c28712",
"children":[
"Cyclophosphamide is used in severe cases of vasculitis and lupus nephritis or when other agents fail."
]
},
{
"type":"keypoint",
"hlId":"45d6ae",
"children":[
"The oral Janus kinase inhibitor tofacitinib is FDA approved for rheumatoid arthritis and psoriatic arthritis and has efficacy equal to that of biologic agents."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_2",
"title":{
"__html":"Biologic Disease-Modifying Antirheumatic Drugs"
},
"titleNode":{
"type":"section-title",
"hlId":"c9ac4a",
"children":[
"Biologic Disease-Modifying Antirheumatic Drugs"
]
},
"children":[
{
"type":"p",
"hlId":"f44c03",
"children":[
"Biologic DMARDs are highly specific, parenterally administered, protein-based agents with extracellular targets (cytokines, cytokine receptors, or cell surface molecules on immune cells) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f01",
"wrapId":"3",
"children":[
"Figure 1"
]
}
]
},
")"
]
},
". The end of the generic name of a biologic agent indicates what type of molecule it is: ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"-mab"
]
},
" indicates a monoclonal antibody, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"-kin"
]
},
" indicates an interleukin-type substance, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"-ra"
]
},
" is for a receptor antagonist, and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"-cept"
]
},
" is for receptor-based molecule. All biologics require parenteral administration."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_rm_f01"
]
},
{
"type":"p",
"hlId":"e97165",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t10",
"wrapId":"4",
"children":[
"Table 10"
]
}
]
},
" and ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t11",
"wrapId":"4",
"children":[
"Table 11"
]
}
]
},
" summarize the structures, targets, indications, and common monitoring parameters of various biologic DMARDs. See ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s2_6",
"children":[
"Medications and Pregnancy"
]
},
" for information on these drugs in pregnancy. Biologic DMARDs increase the risk for infection to varying degrees. Targeted screening is therefore necessary before initiation (see ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s2_7",
"children":[
"Vaccination and Screening in Immunosuppression"
]
},
")."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_rm_t10",
"mk19_b_rm_t11"
]
},
{
"type":"p",
"hlId":"f2a6ba",
"children":[
"The cost of biologic agents is significant and may be a barrier to access."
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_2_1",
"title":{
"__html":"Tumor Necrosis Factor Inhibitors"
},
"titleNode":{
"type":"section-title",
"hlId":"ca870f",
"children":[
"Tumor Necrosis Factor Inhibitors"
]
},
"children":[
{
"type":"p",
"hlId":"840bd8",
"children":[
"Tumor necrosis factor (TNF) inhibitors (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t10",
"wrapId":"5",
"children":[
"Table 10"
]
}
]
},
")"
]
},
" are widely used for treating RA, psoriasis, psoriatic arthritis, and ankylosing spondylitis, as well as several nonrheumatologic diseases."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_rm_t10"
]
},
{
"type":"p",
"hlId":"f69bc1",
"children":[
"TNF inhibitors are generally well tolerated; increased risk for infection is the primary safety concern. Because TNF inhibitors pose a particularly high risk for reactivation of tuberculosis, all patients being considered for treatment must be screened for latent infection and, if needed, receive treatment. Except for nonmelanoma skin cancer and possibly melanoma, TNF inhibitors do not appear to increase the risk for new cancers; the risk for malignant recurrence remains unclear. TNF inhibitors may exacerbate heart failure and rarely provoke a demyelinating condition. Over time, individual TNF inhibitors may lose efficacy owing to formation of antidrug antibodies."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_2_2",
"title":{
"__html":"Other Biologic Disease-Modifying Antirheumatic Drugs"
},
"titleNode":{
"type":"section-title",
"hlId":"f98af8",
"children":[
"Other Biologic Disease-Modifying Antirheumatic Drugs"
]
},
"children":[
{
"type":"p",
"hlId":"a1bb78",
"children":[
"Multiple biologic DMARDs with non-TNF extracellular and cell-surface targets have been approved by the FDA. Most of these agents are started after one or two TNF inhibitors have failed. See ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t11",
"wrapId":"6",
"children":[
"Table 11"
]
}
]
},
" for more information."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_rm_t11"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_4_2_3",
"title":{
"__html":"Biosimilars"
},
"titleNode":{
"type":"section-title",
"hlId":"99e3f6",
"children":[
"Biosimilars"
]
},
"children":[
{
"type":"p",
"hlId":"d3793b",
"children":[
"Biosimilar agents are “copycat” versions of brand-name biologic medications. The drugs are not exact replicas (hence the term “biosimilar”); therefore, they must undergo phase III testing to prove equivalent efficacy to the parent biologic. In the United States, biosimilars are distinguished from their originator molecules by the presence of a four-character alphabetic suffix. Biosimilars hold promise for decreasing cost and improving access, but those benefits have rarely been realized because of regulatory and market factors."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0276d4",
"children":[
"All biologic agents increase the risk for infection; therefore, targeted screening is necessary before initiation."
]
},
{
"type":"keypoint",
"hlId":"2e265a",
"children":[
"Tumor necrosis factor inhibitors pose a particularly high risk for reactivation of tuberculosis, and patients must be screened for latent infection before initiation of therapy."
]
},
{
"type":"keypoint",
"hlId":"9d9757",
"hvc":true,
"children":[
"Biologic agents that are not directed at tumor necrosis factor (TNF) are usually started after one or two TNF inhibitors have failed."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_5",
"title":{
"__html":"Urate-Lowering Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"6f7a43",
"children":[
"Urate-Lowering Therapy"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s2_5_1",
"title":{
"__html":"Allopurinol"
},
"titleNode":{
"type":"section-title",
"hlId":"2e4c04",
"children":[
"Allopurinol"
]
},
"children":[
{
"type":"p",
"hlId":"da287a",
"children":[
"Allopurinol is the recommended first-line urate-lowering agent. It competitively inhibits the enzyme xanthine oxidase, blocking the conversion of hypoxanthine (a breakdown product of purines) to uric acid. Allopurinol is metabolized to oxypurinol, which also inhibits xanthine oxidase. Allopurinol is FDA approved for dosages up to 800 mg/d. Allopurinol should be initiated at 100 mg/d and titrated in 100-mg increments until the therapeutic target is achieved. For patients with stage 4 or 5 chronic kidney disease, allopurinol should be initiated at 50 mg/d and titrated in 50- to 100-mg increments as needed."
]
},
{
"type":"p",
"hlId":"cad1b9",
"children":[
"Allopurinol use is rarely associated with a hypersensitivity syndrome, most severely as DRESS (drug reaction with eosinophilia and systemic symptoms), a potentially fatal reaction. DRESS is also increasingly being referred to as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"drug-induced hypersensitivity syndrome"
]
},
" (DIHS) to emphasize the fact that eosinophilia is not always present. Risk factors include chronic kidney disease and diuretic use; allopurinol dosage titration appears to substantially reduce the risk. Certain HLA polymorphisms also substantially increase the risk for hypersensitivity. Some are associated with different ethnic populations. Screening for HLA-B*58:01 in patients of Korean, Han Chinese, Thai, and African descent is conditionally recommended before initiation of allopurinol. Xanthine oxidase inhibitors should not be coadministered with purine analogues (such as azathioprine). See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s10_5_3",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
" for more information on DRESS."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_5_2",
"title":{
"__html":"Febuxostat"
},
"titleNode":{
"type":"section-title",
"hlId":"5c8086",
"children":[
"Febuxostat"
]
},
"children":[
{
"type":"p",
"hlId":"3933fd",
"children":[
"Febuxostat is a noncompetitive xanthine oxidase inhibitor. Elevated aminotransferase levels can rarely occur, and liver enzymes should be monitored. Concomitant use with purine analogues is contraindicated. Incidence of hypersensitivity is rarer and usually less severe than with allopurinol. In a 2018 safety study, febuxostat users had an increased risk for cardiovascular death and all-cause mortality compared with patients receiving allopurinol. These data do not define febuxostat as raising risk compared with no treatment, and other studies have failed to support this observation; however, the results prompted the FDA to mandate a boxed warning for febuxostat regarding increased risk compared with allopurinol. The FDA has also limited the approved use of febuxostat to patients who are unresponsive to or cannot tolerate allopurinol."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_5_3",
"title":{
"__html":"Uricosuric Agents"
},
"titleNode":{
"type":"section-title",
"hlId":"75cb36",
"children":[
"Uricosuric Agents"
]
},
"children":[
{
"type":"p",
"hlId":"b6bcbd",
"children":[
"Probenecid is an organic acid transport inhibitor that decreases renal reuptake of uric acid. It is uncommonly used because of limited efficacy, inconvenience, and limitations on use (e.g., drug interactions and adverse effects)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_5_4",
"title":{
"__html":"Pegloticase"
},
"titleNode":{
"type":"section-title",
"hlId":"807ef0",
"children":[
"Pegloticase"
]
},
"children":[
{
"type":"p",
"hlId":"8b6ea0",
"children":[
"Unlike most other mammals, humans lack a functioning uricase to break down uric acid. Pegloticase is a recombinant, nonhuman, infusible pegylated uricase that is highly effective at lowering serum urate. Pegloticase is reserved for severe and/or refractory gout. Because of its extreme potency, mobilization flares of gout are common, and prophylaxis against acute gouty attacks is required. Pegloticase is administered intravenously every 2 weeks; if the preinfusion serum urate increases to more than 6.0 mg/dL (0.35 mmol/L) on two occasions, antibodies have probably formed, and the drug should be discontinued to prevent infusion reactions."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"245572",
"children":[
"Allopurinol is the first-line urate-lowering agent; the biggest risk the drug poses is DRESS (drug reaction with eosinophilia and systemic symptoms)."
]
},
{
"type":"keypoint",
"hlId":"994d1e",
"children":[
"Concomitant use of xanthine oxidase inhibitors (allopurinol or febuxostat) with purine analogues is contraindicated."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_6",
"title":{
"__html":"Medications and Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"70849d",
"children":[
"Medications and Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"e5b5eb",
"children":[
"Some rheumatologic medications can have adverse effects on pregnancy. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t12",
"wrapId":"7",
"children":[
"Table 12"
]
}
]
},
" lists these agents and their relative risks."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_rm_t12"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"45d1f2",
"children":[
"Methotrexate is highly teratogenic and abortifacient; it must be discontinued at least 3 months before pregnancy."
]
},
{
"type":"keypoint",
"hlId":"b21fa3",
"children":[
"Hydroxychloroquine is relatively safe in pregnancy and should not be discontinued if it is needed."
]
},
{
"type":"keypoint",
"hlId":"a40ce9",
"children":[
"Leflunomide is extremely teratogenic and must not be used before or during pregnancy; upon discontinuation, cholestyramine is required to remove the drug from the body in all women of childbearing potential and specifically in those wishing to become pregnant."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_7",
"title":{
"__html":"Vaccination and Screening in Immunosuppression"
},
"titleNode":{
"type":"section-title",
"hlId":"8805c1",
"children":[
"Vaccination and Screening in Immunosuppression"
]
},
"children":[
{
"type":"p",
"hlId":"193329",
"children":[
"Patients with autoimmune diseases should be assessed for immunization status at diagnosis and/or initiation of treatments. Whenever possible, patients should be updated with vaccinations at least 2 to 4 weeks before initiating biologic DMARD regimens. Vaccine response may be diminished during biologic immunosuppressive treatment (particularly with B-cell–depleting therapy), and patients receiving biologic DMARDs and/or JAK inhibitors, such as tofacitinib, should not receive live attenuated vaccines (e.g., for measles, mumps and rubella; varicella herpes zoster; influenza; and yellow fever) because of risk for active infection. Such patients can receive the killed influenza and pneumococcal vaccines, as well as recombinant herpes zoster vaccine as needed. Other non-live vaccines that are indicated should be administered as per standard care (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_3",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
" for more information). Patients receiving traditional oral DMARDs (e.g., hydroxychloroquine, low-dose methotrexate, and sulfasalazine) may receive any vaccines as needed."
]
},
{
"type":"p",
"hlId":"716316",
"children":[
"Before initiation of immunosuppressive therapy, the following screening is recommended:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"a67f0c",
"children":[
"Tuberculosis screening with tuberculin skin testing or interferon-γ release assay, particularly for patients initiating biologic DMARDs"
]
},
" ",
{
"type":"list-item",
"hlId":"dddfa6",
"children":[
"Hepatitis B and C virus serologic testing (for patients initiating biologic DMARDs and drugs that can cause hepatotoxicity)"
]
},
" ",
{
"type":"list-item",
"hlId":"0b1e6f",
"children":[
"HIV screening"
]
},
" "
]
},
{
"type":"p",
"hlId":"9b44c5",
"children":[
"Patients with latent or active tuberculosis, active hepatitis B virus infection, or untreated HIV infection require initiation of appropriate therapy before initiating immunosuppression. Patients with risk factors for ongoing tuberculosis exposure should have annual tuberculosis screening."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"a69f6e",
"children":[
"Whenever possible, vaccinations should be updated before initiating biologic disease-modifying antirheumatic drug regimens."
]
},
{
"type":"keypoint",
"hlId":"b6b467",
"children":[
"Screening (and therapy if needed) for tuberculosis, hepatitis B and C virus, and HIV is appropriate before initiation of immunosuppressive therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_8",
"title":{
"__html":"Nonpharmacologic and Nontraditional Management"
},
"titleNode":{
"type":"section-title",
"hlId":"eaedf3",
"children":[
"Nonpharmacologic and Nontraditional Management"
]
},
"children":[
{
"type":"p",
"hlId":"1a5a5e",
"children":[
"Because rheumatologic diseases frequently affect the musculoskeletal system, nonpharmacologic measures are often used to address pain not eliminated by medications. These measures include physical therapy, occupational therapy, surgery, weight reduction, psychosocial support, and self-management programs. Many patients turn to complementary and alternative medicine as adjuncts to traditional medical interventions."
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_8_1",
"title":{
"__html":"Physical and Occupational Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"ebf90e",
"children":[
"Physical and Occupational Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"3d7e85",
"children":[
"Physical therapists can help primary care physicians assess aerobic fitness and conditioning as well as ability to carry out activities of daily living. Pain and functional limitation can be addressed through manual therapy, assistive devices, joint protection techniques, and thermal treatments. A targeted exercise program can be initiated, and adapting the program for home use is critical. Physical therapy referral is appropriate for tendinitis; bursitis; many forms of arthritis; and chronic soft-tissue pain due to overuse, injury, and chronic pain syndromes (e.g., fibromyalgia)."
]
},
{
"type":"p",
"hlId":"7d01e0",
"children":[
"Occupational therapists assess upper extremity functioning, including the ability to perform self-care and job-related tasks. Braces and splints may be provided for painful or unstable joints. An ergonomic evaluation of the workstation may accompany instruction in improved body mechanics and avoidance of repetitive trauma."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_8_2",
"title":{
"__html":"Complementary and Alternative Medicine"
},
"titleNode":{
"type":"section-title",
"hlId":"e40bcf",
"children":[
"Complementary and Alternative Medicine"
]
},
"children":[
{
"type":"p",
"hlId":"047a98",
"children":[
"Nontraditional options for symptom management are used by about one third of patients overall and up to 90% of patients with chronic pain, including arthritis and rheumatologic diseases. Commonly used over-the-counter supplements include fish oil, vitamins, glucosamine, and chondroitin. Providers should ask about supplement use because patients rarely volunteer this information. Significant drug interactions may occur; for example, some herbal preparations can interact with anticoagulants. See ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s5_3_2_1",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
" for discussion of cannabis for pain management."
]
},
{
"type":"p",
"hlId":"2e6422",
"children":[
"Mind-body interventions, such as tai chi, meditation, and yoga, can improve psychological well-being, strength, balance, and pain level. Chiropractic and osteopathic manipulation as well as massage remain popular. Randomized controlled trials support the use of tai chi for arthritis; smaller trials suggest benefit from meditation techniques, yoga, massage, acupuncture, and manipulative medicine for various musculoskeletal problems."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_8_3",
"title":{
"__html":"Role of Surgery"
},
"titleNode":{
"type":"section-title",
"hlId":"3d28c7",
"children":[
"Role of Surgery"
]
},
"children":[
{
"type":"p",
"hlId":"aaba7e",
"children":[
"Surgical procedures, such as carpal tunnel release or rotator cuff tendon repair, can address conditions that arise from repetitive trauma, injury, and degenerative changes in the soft tissue. Synovectomy of inflammatory pannus is occasionally used when a single or limited number of joints in patients with RA do not respond to medications. Total joint arthroplasty, particularly of the knee or hip, can reduce or eliminate pain and restore function in patients with an inadequate response to medication and physical or occupational therapy."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"224a12",
"children":[
"Nonpharmacologic measures used in rheumatologic diseases include physical or occupational therapy, surgery, weight reduction, psychosocial support, and self-management programs."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s2_9",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2017;69:1095-1110. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28585410",
"target":"_blank"
},
"children":[
"PMID: 28585410"
]
},
" doi:10.1002/acr.23279"
]
},
{
"type":"reference",
"children":[
"da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390:e21-e33. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28699595",
"target":"_blank"
},
"children":[
"PMID: 28699595"
]
},
" doi:10.1016/S0140-6736(17)31744-0"
]
},
{
"type":"reference",
"children":[
"FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744-760. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32391934",
"target":"_blank"
},
"children":[
"PMID: 32391934"
]
},
" doi:10.1002/acr.24180"
]
},
{
"type":"reference",
"children":[
"Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39-52. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31413005",
"target":"_blank"
},
"children":[
"PMID: 31413005"
]
},
" doi:10.1136/annrheumdis-2019-215882"
]
},
{
"type":"reference",
"children":[
"Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77:797-807. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29724726",
"target":"_blank"
},
"children":[
"PMID: 29724726"
]
},
" doi:10.1136/annrheumdis-2017-212662"
]
},
{
"type":"reference",
"children":[
"Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80:99-113. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32002851",
"target":"_blank"
},
"children":[
"PMID: 32002851"
]
},
" doi:10.1007/s40265-020-01256-5"
]
},
{
"type":"reference",
"children":[
"Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72:220-233. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31908163",
"target":"_blank"
},
"children":[
"PMID: 31908163"
]
},
" doi:10.1002/art.41142"
]
},
{
"type":"reference",
"children":[
"Mielenz TJ, Xiao C, Callahan LF. Self-management of arthritis symptoms by complementary and alternative medicine movement therapies. J Altern Complement Med. 2016;22:404-7. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27058260",
"target":"_blank"
},
"children":[
"PMID: 27058260"
]
},
" doi:10.1089/acm.2015.0222"
]
},
{
"type":"reference",
"children":[
"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1-26. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26545940",
"target":"_blank"
},
"children":[
"PMID: 26545940"
]
},
" doi:10.1002/art.39480"
]
},
{
"type":"reference",
"children":[
"Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685-699. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31969328",
"target":"_blank"
},
"children":[
"PMID: 31969328"
]
}
]
},
{
"type":"reference",
"children":[
"White WB, Saag KG, Becker MA, et al; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200-1210. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29527974",
"target":"_blank"
},
"children":[
"PMID: 29527974"
]
},
" doi:10.1056/NEJMoa1710895"
]
},
{
"type":"reference",
"children":[
"Yang SC, Lai YY, Huang MC, et al. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus. 2018;27:1819-1827. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30103646",
"target":"_blank"
},
"children":[
"PMID: 30103646"
]
},
" doi:10.1177/0961203318792352"
]
},
{
"type":"reference",
"children":[
"US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. September 16, 2021. Accessed October 6, 2021. Available at: ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death",
"target":"_blank"
},
"children":[
"https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"
]
},
"."
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_rm_t08":{
"id":"mk19_b_rm_t08",
"number":8,
"bookId":"rm",
"title":{
"__html":"Potential Toxicities of NSAID Use"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"4afc01",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 8. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t08"
}
]
},
"Potential Toxicities of NSAID Use"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3adbdb",
"class":"col hd l",
"children":[
"Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"688250",
"class":"col hd l",
"children":[
"Toxicity"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"59ea4b",
"class":"cell txt l",
"children":[
"Cardiovascular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fd0fd",
"class":"cell txt l",
"children":[
"Myocardial infarction; exacerbation of heart failure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0ce39e",
"class":"cell txt l",
"children":[
"Hemostatic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4225b9",
"class":"cell txt l",
"children":[
"Platelet dysfunction"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef024b",
"class":"cell txt l",
"children":[
"Gastrointestinal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bc97da",
"class":"cell txt l",
"children":[
"Dyspepsia; reflux; peptic ulcer disease; gastrointestinal bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"883ac5",
"class":"cell txt l",
"children":[
"Obstetric/Gynecologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e9fbe",
"class":"cell txt l",
"children":[
"Bleeding; delayed labor; premature ductus arteriosus closure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a36efb",
"class":"cell txt l",
"children":[
"Pulmonary"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3aff16",
"class":"cell txt l",
"children":[
"Asthma exacerbation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"199d35",
"class":"cell txt l",
"children":[
"Renal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"12874e",
"class":"cell txt l",
"children":[
"Hypertension; decreased glomerular filtration; increased salt and water retention; increased renin production; uncommonly, allergic interstitial nephritis or acute tubular necrosis"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_rm_t09":{
"id":"mk19_b_rm_t09",
"number":9,
"bookId":"rm",
"title":{
"__html":"Nonbiologic Disease-Modifying Antirheumatic Drugs"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3e1c2d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 9. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t09"
}
]
},
"Nonbiologic Disease-Modifying Antirheumatic Drugs"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da0b90",
"class":"col hd l",
"children":[
"Mechanisms of Action"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b670b8",
"class":"col hd l",
"children":[
"Indications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"55422e",
"class":"col hd l",
"children":[
"Common Monitoring Parameters"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98cff",
"class":"cell txt l",
"children":[
"Methotrexate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1ed49",
"class":"cell txt l",
"children":[
"Low dose: anti-inflammatory agent via up-regulation of adenosine A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2A"
]
},
" signaling"
]
},
" ",
{
"type":"p",
"hlId":"22c181",
"class":"cell txt l",
"children":[
"High dose: antimetabolite/folate antagonist used in neoplastic disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"edfadf",
"class":"cell txt l",
"children":[
"RA; psoriasis; psoriatic arthritis; IBD; SLE (arthritis only); reactive arthritis; DM; PM; vasculitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"925a29",
"class":"cell txt l",
"children":[
"Baseline: chest radiography, hepatitis screening, CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"3e9749",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine after first month, then approximately every 2-3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"476428",
"class":"cell txt l",
"children":[
"Hydroxychloroquine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70dd49",
"class":"cell txt l",
"children":[
"Uncertain; appears to involve stabilization of lysosomal vacuoles, leading to inhibition of antigen processing and/or inhibition of Toll-like receptor activation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"effc9e",
"class":"cell txt l",
"children":[
"SLE; RA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"f20e1e",
"class":"cell txt l",
"children":[
"Retinal examinations at baseline and annual examination after 5 years of therapy to evaluate for retinopathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"121888",
"class":"cell txt l",
"children":[
"Sulfasalazine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80e60e",
"class":"cell txt l",
"children":[
"Unknown; the prodrug is broken down into 5-amino salicylic acid (active metabolite in gastrointestinal tract) and sulfapyridine (exerts systemic action)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a446db",
"class":"cell txt l",
"children":[
"RA; SpA; IBD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"fa1ad7",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 3-6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14a480",
"class":"cell txt l",
"children":[
"Leflunomide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f457d",
"class":"cell txt l",
"children":[
"Inhibits mitochondrial enzyme dihydroorotate dehydrogenase to block pyrimidine synthesis (decreasing lymphocyte production); antiproliferative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dbacce",
"class":"cell txt l",
"children":[
"RA; psoriatic arthritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21f6b4",
"class":"cell txt l",
"children":[
"Baseline: hepatitis screening, CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"391423",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine after 4 weeks, then every 3 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac0373",
"class":"cell txt l",
"children":[
"Azathioprine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34b681",
"class":"cell txt l",
"children":[
"Prodrug of 6-mercaptopurine; purine analogue; inhibits DNA synthesis essential for proliferating T and B lymphocytes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8cf71",
"class":"cell txt l",
"children":[
"SLE; DM; PM; vasculitis; IBD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"cece88",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ce44b",
"class":"cell txt l",
"children":[
"Cyclophosphamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"797df4",
"class":"cell txt l",
"children":[
"Alkylating agent; blocks DNA synthesis and causes cell death, especially of T cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfc49e",
"class":"cell txt l",
"children":[
"Severe and life-threatening complications in SLE, DM, PM, and vasculitis; may be used when other agents fail"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b1e05",
"class":"cell txt l",
"children":[
"Close monitoring clinically and measuring CBC, chemistries, LCTs, urinalysis every 4-8 weeks"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31de20",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8969b",
"class":"cell txt l",
"children":[
"Active metabolite (mycophenolic acid) inhibits purine synthesis; preferentially inhibits T and B lymphocytes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc5b81",
"class":"cell txt l",
"children":[
"SLE (especially lupus nephritis); vasculitis (maintenance therapy); DM; PM; SSc"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"76a311",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine after 4 weeks and then every 3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"955334",
"class":"cell txt l",
"children":[
"Cyclosporine, voclosporin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a74ad",
"class":"cell txt l",
"children":[
"Inhibit calcineurin (transcription activating factor); preferentially target T cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97ae39",
"class":"cell txt l",
"children":[
"SLE; psoriasis; RA (cyclosporine)"
]
},
" ",
{
"type":"p",
"hlId":"f8060b",
"class":"cell txt l",
"children":[
"Lupus nephritis (voclosporin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"33a9ef",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 2-3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f5702",
"class":"cell txt l",
"children":[
"Tofacitinib, baricitinib, upadacitinib"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d70c2d",
"class":"cell txt l",
"children":[
"Janus kinase inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b113c",
"class":"cell txt l",
"children":[
"RA (tofacitinib, baricitinib, upadacitinib)"
]
},
" ",
{
"type":"p",
"hlId":"917415",
"class":"cell txt l",
"children":[
"Psoriatic arthritis (tofacitinib)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cbd82",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine, lipid panel"
]
},
" ",
{
"type":"p",
"hlId":"58bedd",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 8 weeks, lipids after 8 weeks and then every 6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1b7af",
"class":"cell txt l",
"children":[
"Apremilast"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c5790",
"class":"cell txt l",
"children":[
"Phosphodiesterase-4 inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35ad78",
"class":"cell txt l",
"children":[
"Psoriasis; psoriatic arthritis; oral ulcers associated with Behçet syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9ffa1",
"class":"cell txt l",
"children":[
"Baseline: weight"
]
},
" ",
{
"type":"p",
"hlId":"1abc6d",
"class":"cell txt l",
"children":[
"Thereafter: weight, neuropsychiatric effects"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CBC = complete blood count; DM = dermatomyositis; IBD = inflammatory bowel disease; LCT = liver chemistry test; PM = polymyositis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SpA = spondyloarthritis; SSc = systemic sclerosis."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Recommended monitoring interval is for a stable dose but may be shorter after initiation or in the case of abnormal results; must be individualized to the patient's risk for toxicity."
]
]
},
"mk19_b_rm_t10":{
"id":"mk19_b_rm_t10",
"number":10,
"bookId":"rm",
"title":{
"__html":"Tumor Necrosis Factor Inhibitors<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"eaf63f",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 10. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t10"
}
]
},
"Tumor Necrosis Factor Inhibitors",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27b1db",
"class":"col hd l",
"children":[
"Agent Structure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b670b8",
"class":"col hd l",
"children":[
"Indications"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14e606",
"class":"cell txt l",
"children":[
"Infliximab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"481595",
"class":"cell txt l",
"children":[
"Chimeric (mouse-human) monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"892307",
"class":"cell txt l",
"children":[
"RA; psoriatic arthritis; ankylosing spondylitis; IBD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a43071",
"class":"cell txt l",
"children":[
"Adalimumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"892307",
"class":"cell txt l",
"children":[
"RA; psoriatic arthritis; ankylosing spondylitis; IBD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b49f94",
"class":"cell txt l",
"children":[
"Etanercept"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c60f76",
"class":"cell txt l",
"children":[
"Fusion protein made of two p75 TNF receptors linked to IgG Fc segment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ade40b",
"class":"cell txt l",
"children":[
"RA; psoriatic arthritis; ankylosing spondylitis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16599c",
"class":"cell txt l",
"children":[
"Certolizumab pegol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65ea62",
"class":"cell txt l",
"children":[
"Fab’ segment of humanized monoclonal antibody attached to polyethylene glycol strands"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ade40b",
"class":"cell txt l",
"children":[
"RA; psoriatic arthritis; ankylosing spondylitis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ab32c",
"class":"cell txt l",
"children":[
"Golimumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ade40b",
"class":"cell txt l",
"children":[
"RA; psoriatic arthritis; ankylosing spondylitis"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IBD = inflammatory bowel disease; RA = rheumatoid arthritis; TNF = tumor necrosis factor."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Common monitoring parameters for TNF inhibitors include tuberculosis, fungal, and other infections as well as complete blood count, serum creatinine, and liver chemistry tests at baseline and every 3 to 6 months thereafter."
]
]
},
"mk19_b_rm_t11":{
"id":"mk19_b_rm_t11",
"number":11,
"bookId":"rm",
"title":{
"__html":"Other Biologic Disease-Modifying Antirheumatic Drugs<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"34b7bd",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 11. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t11"
}
]
},
"Other Biologic Disease-Modifying Antirheumatic Drugs",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27b1db",
"class":"col hd l",
"children":[
"Agent Structure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c41a31",
"class":"col hd l",
"children":[
"Target"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b670b8",
"class":"col hd l",
"children":[
"Indications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42b72b",
"class":"cell txt l",
"children":[
"Abatacept"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bef53a",
"class":"cell txt l",
"children":[
"Soluble CTLA4 receptor/IgG Fc segment chimera"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d812f",
"class":"cell txt l",
"children":[
"CD80/CD86; blocks T-cell costimulation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36fb81",
"class":"cell txt l",
"children":[
"RA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"afd128",
"class":"cell txt l",
"children":[
"Preferred for patients with history of severe infection; relatively contraindicated in COPD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fad6a2",
"class":"cell txt l",
"children":[
"Rituximab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"481595",
"class":"cell txt l",
"children":[
"Chimeric (mouse-human) monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f9f8c",
"class":"cell txt l",
"children":[
"CD20",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
" B cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe9dc1",
"class":"cell txt l",
"children":[
"RA; ANCA-associated vasculitis; occasionally for SLE (off-label); IgG4-related disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a308f",
"class":"cell txt l",
"children":[
"Given as intravenous infusion over several hours; has higher risk for infusion reactions than other biologic DMARDs; can cause hypogammaglobulinemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2aee23",
"class":"cell txt l",
"children":[
"Tocilizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ffe30",
"class":"cell txt l",
"children":[
"IL-6 receptor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0be2c9",
"class":"cell txt l",
"children":[
"RA; JIA; Castleman disease; GCA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30c8c6",
"class":"cell txt l",
"children":[
"Can cause elevated aminotransferase levels, hyperlipidemia, leukopenia, thrombocytopenia; avoid in patients with history of diverticulitis because of attendant risk for bowel perforation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40a580",
"class":"cell txt l",
"children":[
"Sarilumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ffe30",
"class":"cell txt l",
"children":[
"IL-6 receptor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36fb81",
"class":"cell txt l",
"children":[
"RA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6daeef",
"class":"cell txt l",
"children":[
"Can cause elevated aminotransferase levels, hyperlipidemia, leukopenia, thrombocytopenia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e24cc5",
"class":"cell txt l",
"children":[
"Belimumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c242eb",
"class":"cell txt l",
"children":[
"BLyS/BAFF"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64e67e",
"class":"cell txt l",
"children":[
"SLE; lupus nephritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31cf0a",
"class":"cell txt l",
"children":[
"Phase III trials showed small but statistically significant improvement versus standard therapy alone, with glucocorticoid-sparing effect"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d8182",
"class":"cell txt l",
"children":[
"Ustekinumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba4c44",
"class":"cell txt l",
"children":[
"IL-12/IL-23"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"830d77",
"class":"cell txt l",
"children":[
"Psoriasis; psoriatic arthritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbc65",
"class":"cell txt l",
"children":[
"Injectable; less robust effect than other biologic DMARDs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3b6ad",
"class":"cell txt l",
"children":[
"Secukinumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d62f88",
"class":"cell txt l",
"children":[
"IL-17a"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"503c9f",
"class":"cell txt l",
"children":[
"Psoriatic arthritis; ankylosing spondylitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9cbbbc",
"class":"cell txt l",
"children":[
"Phase III trials suggest efficacy equal to that of TNF inhibitors; can cause IBD flares"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c44ef3",
"class":"cell txt l",
"children":[
"Ixekizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d62f88",
"class":"cell txt l",
"children":[
"IL-17a"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"503c9f",
"class":"cell txt l",
"children":[
"Psoriatic arthritis; ankylosing spondylitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9cbbbc",
"class":"cell txt l",
"children":[
"Phase III trials suggest efficacy equal to that of TNF inhibitors; can cause IBD flares"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de978f",
"class":"cell txt l",
"children":[
"Guselkumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6e56e",
"class":"cell txt l",
"children":[
"IL-23"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"830d77",
"class":"cell txt l",
"children":[
"Psoriasis; psoriatic arthritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d6b42",
"class":"cell txt l",
"children":[
"Selective IL-23 inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c82074",
"class":"cell txt l",
"children":[
"Anakinra"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4f3bb",
"class":"cell txt l",
"children":[
"Recombinant receptor antagonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee6a00",
"class":"cell txt l",
"children":[
"IL-1β receptor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c9495",
"class":"cell txt l",
"children":[
"RA; CAPS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; AOSD (off-label); acute gouty arthritis (off-label)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f432f8",
"class":"cell txt l",
"children":[
"Rarely used in RA because efficacy is inferior to that of other biologic DMARDs; reversible neutropenia can develop"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ecd2af",
"class":"cell txt l",
"children":[
"Canakinumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b723d9",
"class":"cell txt l",
"children":[
"IL-1β"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d617c",
"class":"cell txt l",
"children":[
"CAPS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"767a1d",
"class":"cell txt l",
"children":[
"More expensive IL-1β inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7df1c5",
"class":"cell txt l",
"children":[
"Rilonacept"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"543ea7",
"class":"cell txt l",
"children":[
"Dual IL-1β receptors chimerically attached to IgG Fc segment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a71551",
"class":"cell txt l",
"children":[
"IL-1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a06e9",
"class":"cell txt l",
"children":[
"CAPS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; refractory gout"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1ded8",
"class":"cell txt l",
"children":[
"More expensive IL-1 inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b450a0",
"class":"cell txt l",
"children":[
"Mepolizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da1085",
"class":"cell txt l",
"children":[
"IL-5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f7c9a",
"class":"cell txt l",
"children":[
"EGPA; eosinophilic asthma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb0ba9",
"class":"cell txt l",
"children":[
"Only biologic approved for treatment of EGPA"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"AOSD = adult-onset Still disease; BAFF = B-cell–activating factor; BLyS = B-lymphocyte stimulator; CAPS = cryopyrin-associated periodic syndromes; DMARD = disease-modifying antirheumatic drug; EGPA = eosinophilic granulomatosis with polyangiitis; GCA = giant cell arteritis; IBD = inflammatory bowel disease; IL = interleukin; JIA = juvenile idiopathic arthritis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; TNF = tumor necrosis factor."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Before initiation of any biologic, tuberculosis screening must be performed. Complete blood counts should be performed every 3 to 6 months for all biologics, and aspartate aminotransferase/alanine aminotransferase and a lipid panel should be checked every 2 to 3 months for tocilizumab."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"The cryopyrin-associated periodic syndromes (CAPS) include familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (chronic infantile neurologic, cutaneous, articular syndrome)."
]
]
},
"mk19_b_rm_t12":{
"id":"mk19_b_rm_t12",
"number":12,
"bookId":"rm",
"title":{
"__html":"Rheumatologic Medications and Pregnancy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a4c0f8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 12. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t12"
}
]
},
"Rheumatologic Medications and Pregnancy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"941082",
"class":"col hd l",
"children":[
"Medication/Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d19ff",
"class":"col hd l",
"children":[
"Anti-Inflammatory Agents"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3bf03",
"class":"cell txt l",
"children":[
"NSAIDs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10a2a5",
"class":"cell txt l",
"children":[
"May impede implantation and be associated with small increased risk for miscarriage when used before 20 weeks' gestation. NSAID use after 30 weeks' gestation can lead to premature closure of ductus arteriosus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adb71f",
"class":"cell txt l",
"children":[
"Glucocorticoids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c402c4",
"class":"cell txt l",
"children":[
"When taken in first trimester, can increase risk for fetal cleft palate and raise risk for maternal gestational diabetes throughout the pregnancy."
]
},
" ",
{
"type":"p",
"hlId":"5bd7ed",
"class":"cell txt l",
"children":[
"Useful in managing active autoimmune disease in pregnancy. Nonfluorinated glucocorticoids (e.g., prednisone, prednisolone, methylprednisolone) have limited ability to cross placenta and are preferred, except when treating the fetus (e.g., neonatal lupus erythematosus)."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56ec19",
"class":"cell txt l",
"children":[
"Colchicine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f68502",
"class":"cell txt l",
"children":[
"Should be used only if potential benefit justifies potential risk to fetus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"3d3c34",
"class":"col hd l",
"children":[
"Analgesics and Pain Pathway Modulators"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"07d079",
"class":"cell txt l",
"children":[
"Acetaminophen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2883d",
"class":"cell txt l",
"children":[
"Generally considered safe at standard dosing but does cross the placenta."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"508714",
"class":"cell txt l",
"children":[
"Opiates"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86adc5",
"class":"cell txt l",
"children":[
"Some opiates/opioids cross placenta; may cause fetal opioid withdrawal at birth."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"85e01b",
"class":"cell txt l",
"children":[
"Tramadol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4256bd",
"class":"cell txt l",
"children":[
"Should be used only if potential benefit justifies potential risk to fetus; postmarketing reports suggest possibility of neonatal seizures, withdrawal syndrome, and stillbirth."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56509c",
"class":"cell txt l",
"children":[
"Topical agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"444e30",
"class":"cell txt l",
"children":[
"Topical use may limit serum levels; individual agents should be reviewed for pregnancy impact before use."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"88a13d",
"class":"col hd l",
"children":[
"Nonbiologic DMARDs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98cff",
"class":"cell txt l",
"children":[
"Methotrexate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2ae4e",
"class":"cell txt l",
"children":[
"Highly teratogenic and abortifacient; must be discontinued at least 3 months before pregnancy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"476428",
"class":"cell txt l",
"children":[
"Hydroxychloroquine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"024511",
"class":"cell txt l",
"children":[
"Relatively safe in pregnancy and should not be discontinued if it is needed."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"121888",
"class":"cell txt l",
"children":[
"Sulfasalazine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bc6b52",
"class":"cell txt l",
"children":[
"Relatively safe during pregnancy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14a480",
"class":"cell txt l",
"children":[
"Leflunomide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"971357",
"class":"cell txt l",
"children":[
"Extremely teratogenic; must not be used before/during pregnancy; upon discontinuation, cholestyramine administration is required to remove drug from the body in all women of childbearing potential and specifically in those wishing to become pregnant; should be followed up with measurement of leflunomide and its metabolite levels to ensure removal of drug."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac0373",
"class":"cell txt l",
"children":[
"Azathioprine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62c8cc",
"class":"cell txt l",
"children":[
"Routine use in pregnancy is not recommended; however, azathioprine may be safer than some other DMARDs and may be used if immunosuppressive agent is imperative."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ce44b",
"class":"cell txt l",
"children":[
"Cyclophosphamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1b5b8",
"class":"cell txt l",
"children":[
"Not used in pregnancy unless absolutely necessary."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31de20",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aca65b",
"class":"cell txt l",
"children":[
"Teratogenic; should not be used in pregnancy; discontinue for 3 months before pregnancy is attempted."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5ad08",
"class":"cell txt l",
"children":[
"Cyclosporine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"240e81",
"class":"cell txt l",
"children":[
"May be used in pregnancy only if benefits outweigh risks."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62a0e6",
"class":"cell txt l",
"children":[
"Tofacitinib; baricitinib; upadacitinib"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19471e",
"class":"cell txt l",
"children":[
"May be teratogenic at high doses."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"4333b9",
"class":"col hd l",
"children":[
"Biologic DMARDs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9a2b1",
"class":"cell txt l",
"children":[
"TNF inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06c8d2",
"class":"cell txt l",
"children":[
"Accumulating retrospective data suggest low risk in pregnancy, but evidence is limited; can be continued if absolutely needed; different agents may have different considerations regarding crossing placenta."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"039f3d",
"class":"cell txt l",
"children":[
"Ustekinumab; anakinra; secukinumab; sarilumab; ixekizumab; guselkumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"226973",
"class":"cell txt l",
"children":[
"Should be used only if potential benefit justifies undefined risk to fetus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a38f1b",
"class":"cell txt l",
"children":[
"Abatacept; belimumab; canakinumab; rilonacept; rituximab; tocilizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f68502",
"class":"cell txt l",
"children":[
"Should be used only if potential benefit justifies potential risk to fetus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e265d",
"class":"col hd l",
"children":[
"Urate-Lowering Therapy (rarely needed in premenopausal women)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e4c04",
"class":"cell txt l",
"children":[
"Allopurinol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f68502",
"class":"cell txt l",
"children":[
"Should be used only if potential benefit justifies potential risk to fetus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c8086",
"class":"cell txt l",
"children":[
"Febuxostat"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f68502",
"class":"cell txt l",
"children":[
"Should be used only if potential benefit justifies potential risk to fetus."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae3e37",
"class":"cell txt l",
"children":[
"Probenecid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d45254",
"class":"cell txt l",
"children":[
"No current evidence for adverse impact on pregnancy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"807ef0",
"class":"cell txt l",
"children":[
"Pegloticase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f68502",
"class":"cell txt l",
"children":[
"Should be used only if potential benefit justifies potential risk to fetus."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DMARD = disease-modifying antirheumatic drug; TNF = tumor necrosis factor."
]
]
}
}
}